May 14, 2009
Cimzia approved for rheumatoid arthritis
Cimzia will now also be available in a prefilled syringe, in addition to the single dose vials of lyophilized powder for subcutaneous injection after reconstitution, which is already on the market. Cimzia is already indicated in moderately to severely active Crohn's disease to reduce signs and symptoms and to maintain clinical response in adult patients with inadequate response to conventional therapy.
For more information call (800) 234-5535 or visit www.Cimzia.com.